Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth
- PMID: 9266706
- DOI: 10.1111/j.1432-1033.1997.00625.x
Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth
Abstract
CYP3A isoforms are responsible for the biotransformation of a wide variety of exogenous chemicals and endogenous steroids in human tissues. Two members of the CYP3A subfamily display developmentally regulated expression in the liver; CYP3A7 is expressed in the fetal liver, whereas CYP3A4 is the major cyrochrome P-450 isoform present in the adult liver. To gain insight into the descriptive ontogenesis of CYP3A isoforms during the neonatal period, we have developed several approaches to explore a neonatal liver bank. Although CYP3A4 and CYP3A7 are structurally closely related, they differ in their capacity to carry out monooxygenase reactions. We have cloned CYP3A4 and CYP3A7 and established stable transfectants in Ad293 cells to investigate their substrate specificities. The 16alpha hydroxylation of dehydroepiandrosterone is catalyzed by both proteins, but CYP3A7 has a higher affinity and maximal velocity than CYP3A4. Conversely, the conversion of testosterone into its 6beta derivative is essentially supported by CYP3A4. We used these two probes to determine the ontogenic evolution at the protein level; CYP3A7 was very active in the fetal liver and its activity was maximal during the first week following birth before to progressively decline and reached a very low level in adult livers. Conversely, the activity of CYP3A4 was extremely weak in the fetus and began to raise after birth to reach 30-40% of the adult activity after one month. CYP3A4 RNA accumulation displays a similar pattern of evolution; when probed with an oligonucleotide, its concentration increased rapidly after birth to reach a plateau as soon as the first week of age. These data supports the assumption that CYP3A4 expression is transcriptionally activated during the first week after birth and is accompanied by a simultaneous decrease of CYP3A7 expression, in such a way that the overall CYP3A protein content and the level of pentoxyresorufin dealkylase catalyzed by the two proteins remain nearly constant.
Similar articles
-
Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells.Biochim Biophys Acta. 1998 May 8;1380(3):297-304. doi: 10.1016/s0304-4165(97)00156-6. Biochim Biophys Acta. 1998. PMID: 9555064
-
Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta.J Clin Invest. 1993 Aug;92(2):1018-24. doi: 10.1172/JCI116607. J Clin Invest. 1993. PMID: 8349787 Free PMC article.
-
Developmental expression of the major human hepatic CYP3A enzymes.J Pharmacol Exp Ther. 2003 Nov;307(2):573-82. doi: 10.1124/jpet.103.054841. Epub 2003 Sep 15. J Pharmacol Exp Ther. 2003. PMID: 12975492
-
Genetic contribution to variable human CYP3A-mediated metabolism.Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94. doi: 10.1016/s0169-409x(02)00066-2. Adv Drug Deliv Rev. 2002. PMID: 12406645 Review.
-
Cytochrome P450 3A: ontogeny and drug disposition.Clin Pharmacokinet. 1999 Dec;37(6):485-505. doi: 10.2165/00003088-199937060-00004. Clin Pharmacokinet. 1999. PMID: 10628899 Review.
Cited by
-
Mechanism Underlying Conflicting Drug-Drug Interaction Between Aprepitant and Voriconazole via Cytochrome P450 3A4-Mediated Metabolism.Yonago Acta Med. 2024 Jan 24;67(1):31-40. doi: 10.33160/yam.2024.02.004. eCollection 2024 Feb. Yonago Acta Med. 2024. PMID: 38371278 Free PMC article.
-
Characterization of CYP3A5 Selective Inhibitors for Reaction Phenotyping of Drug Candidates.AAPS J. 2024 Feb 16;26(2):26. doi: 10.1208/s12248-024-00894-x. AAPS J. 2024. PMID: 38366061
-
Multicenter Population Pharmacokinetics of Fentanyl in Neonatal Surgical Patients Using Dried Blood Spot Specimen Collection Demonstrates Maturation of Elimination Clearance.Anesth Analg. 2024 Feb 1;138(2):447-455. doi: 10.1213/ANE.0000000000006808. Epub 2024 Jan 12. Anesth Analg. 2024. PMID: 38215717
-
Physiologically Based Pharmacokinetic Modeling in Neonates: Current Status and Future Perspectives.Pharmaceutics. 2023 Dec 12;15(12):2765. doi: 10.3390/pharmaceutics15122765. Pharmaceutics. 2023. PMID: 38140105 Free PMC article. Review.
-
Physiologically Based Pharmacokinetics Modeling in the Neonatal Population-Current Advances, Challenges, and Opportunities.Pharmaceutics. 2023 Nov 3;15(11):2579. doi: 10.3390/pharmaceutics15112579. Pharmaceutics. 2023. PMID: 38004559 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
